156 related articles for article (PubMed ID: 38480922)
1. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ; Logun M; Fraietta JA; Wang X; Desai AS; Bagley LJ; Nabavizadeh A; Jarocha D; Martins R; Maloney E; Lledo L; Stein C; Marshall A; Leskowitz R; Jadlowsky JK; Christensen S; Oner BS; Plesa G; Brennan A; Gonzalez V; Chen F; Sun Y; Gladney W; Barrett D; Nasrallah MP; Hwang WT; Ming GL; Song H; Siegel DL; June CH; Hexner EO; Binder ZA; O'Rourke DM
Nat Med; 2024 May; 30(5):1320-1329. PubMed ID: 38480922
[TBL] [Abstract][Full Text] [Related]
2. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
3. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
7. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
[TBL] [Abstract][Full Text] [Related]
8. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
9. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
10. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
11. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
12. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
[TBL] [Abstract][Full Text] [Related]
13. Intracranial CAR-T cell delivery in glioblastoma patients.
Vaughn-Beaucaire P; Choi MJ; Liang O; Lawler SE
Trends Cancer; 2024 Jun; 10(6):478-480. PubMed ID: 38777680
[TBL] [Abstract][Full Text] [Related]
14. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
[TBL] [Abstract][Full Text] [Related]
16. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Brown CE; Alizadeh D; Starr R; Weng L; Wagner JR; Naranjo A; Ostberg JR; Blanchard MS; Kilpatrick J; Simpson J; Kurien A; Priceman SJ; Wang X; Harshbarger TL; D'Apuzzo M; Ressler JA; Jensen MC; Barish ME; Chen M; Portnow J; Forman SJ; Badie B
N Engl J Med; 2016 Dec; 375(26):2561-9. PubMed ID: 28029927
[TBL] [Abstract][Full Text] [Related]
17. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
18. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
[TBL] [Abstract][Full Text] [Related]
20. IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas.
Killock D
Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38514882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
